Company Overview and News

0
Balrampur Chini Mills Limited - Financial Results Updates

2018-06-18 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
BALRAMCHIN 500038

0
Sugar stocks ‘sweeten’ on reports of bailout package

2018-06-05 thehindubusinessline
Sugar stocks rose up to 7 per cent today amid reports that the government is likely to announce a bailout package of over Rs 7,000 crore to ensure cash-starved mills clear dues to farmers at the earliest.
BAJAJHIND MAWANASUG BALRAMCHIN 523371 UTTAMSUGAR 532729 500119 500038 500032 DHAMPURSUG

0
State Street Active Emerging Markets sells Balrampur Chini shares worth Rs 10 cr

2018-06-02 moneycontrol
State Street Active Emerging Markets Small Cap Active Non Lending QIB Common Trust Fund sold nearly 0.6 percent stake in sugar company Balrampur Chini Mills on Friday.
BALRAMCHIN 500038

0
Balrampur Chini Mills Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-05-31 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
BALRAMCHIN 500038

0
Balrampur Chini Mills Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-05-23 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
BALRAMCHIN 500038

0
Balrampur Chini Mills surges 10% despite net loss in Q4

2018-05-21 moneycontrol
Shares of Balrampur Chini Mills surged nearly 10 percent intraday Monday amid reported net loss in the quarter ended March 2018.
BALRAMCHIN 500038

0
Balrampur Chini Mills Limited - Dividend Updates

2018-05-21 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
BALRAMCHIN 500038

0
Morgan Stanley France sells 11.45 lakh shares of Balrampur Chini Mills

2018-05-19 moneycontrol
On May 18, 2018 California Public Employees Retirement System bought 12,85,254 shares of Balrampur Chini Mills at Rs 62.27 on the NSE.
BALRAMCHIN 500038

0
Balrampur Chini Mills Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-05-18 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
BALRAMCHIN 500038

0
Four cos added to MSCI India index

2018-05-15 moneycontrol
As many as four companies - Avenue Supermarts, Biocon, HDFC Standard Life Insurance Company and InterGlobe Aviation - will be added to the MSCI India Index with effect from June 1. The news triggered buying in most of these companies, with shares of Avenue Supermarts surging 6.5 percent to Rs 1,516.80 on BSE.
BALRAMCHIN PWQFY INDIANB INDIGO 532814 532810 539448 539437 PFC IDFCBANK 500038 ASTRAZEN 506820

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

1h - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

1h - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...